JavaScript NENÍ povolen !

Prosím povolte JavaScript.

* Zobrazit nápovědu

Reset

MeSH: cefalexin

27 záznamů v Medvik Filtry

Článek

Cefalosporiny

Urbášková, Pavla
Autor Autorita Národní referenční laboratoř pro antibiotika, Státní zdravotní ústav, Praha

Praktický lékař. 2016 ; 96 (1) : 32-50.

ISSN 0032-6739
Medvik
Zdroj

Článek

Možnosti farmakoterapie v léčbě pacientů se syndromem diabetické nohy
[Pharmacotherapy options in treating patients with diabetic foot syndrome]

Piťhová, Pavlína, 1965-
Autor Autorita ORCID Interní klinika 2. LF UK a FN Motol, Praha

Klinická farmakologie a farmacie. 2015 ; 29 (1) : 25-28.

ISSN 1212-7973
Medvik
Zdroj

Syndromem diabetické nohy označujeme destruktivní postižení tkání dolních končetin diabetiků distálně od kotníku, jehož následkem jsou rozsáhlé ulcerace, gangrény a v krajních případech i nutnost amputace končetiny. Hlavní faktory, které vedou ke vzniku diabetické nohy, jsou diabetická neuropatie (senzomotorická a viscerální), ischemie končetiny (angiopatie), snížení kloubní pohyblivosti a působení tlaku na plosku nohy. Na vzniku a obtížném hojení ulcerací se často podílí infekce. Z přítomnosti těchto faktorů potom vyplývá i léčebná strategie, v níž se významně uplatňuje i použití farmakoterapie. Jedná se zejména o antibiotickou, antiagregační/antikoagulační léčbu a ovlivnění mikrocirkulace. V textu rozebíráme jednotlivé možnosti farmakoterapie.

Diabetic foot syndrome refers to a foot that exhibits pathological changes below the ankle – ulcerations or gangrenes that result directly from diabetes mellitus. The major factors that can cause the diabetic foot syndrome are diabetic neuropathy, limb ischaemia (angiopathy), limited joint mobility, and plantar pressure. Healing is complicated by infection. These factors should be targeted in our treatment strategy that includes pharmacotherapy as well. Antimicrobial, antiplatelet/anticoagulant treatment and drugs improving microcirculation are mainly used

Článek

Výskyt pozdní hematogenní infekce kloubních náhrad v našem souboru a návrh systému prevence
[Late hematogenous infection of prosthetic joints in our patients and proposal for a system of prevention]

Acta chirurgiae orthopaedicae et traumatologiae Čechoslovaca. 2007 ; 74 (6) : 397-400.

ISSN 0001-5415
Medvik
Zdroj

PURPOSE OF THE STUDY To design a prophylactic strategy for late hematogenous infection is not an easy task. It requires the assessment of risk factors for the patient as well as of a potential source of bacteremia. Cost effectiveness, efficacy of the antibiotic selected and complications associated with antibiotic treatment, such as allergic reactions and development of resistance to the antibiotic given, should also be considered. The aim of this retrospective study is to evaluate the occurrence of late hematogenous infection in our large group of patients, to analyze risk factors and to suggest an optimal system of antibiotic prophylaxis in order to prevent the development of this unwelcome complication. MATERIAL AND METHODS Since our objective was to include a large number of patients, a retrospective study was chosen as the method used. The patients treated for infectious complications of total joint replacement at the 1st Department of Orthopaedics, Teaching Hospital in Motol, 1st Faculty of Medicine, Charles University, in the years 1991 through 2004, were evaluated with the use of a targeted questionnaire and complete medical records. The group comprised 229 patients, 149 women and 80 men. Of these, 123 were treated for infection of total hip replacement, 102 for total knee replacement, two had infection of prosthetic shoulder joints and two had infection of elbow joint alloplasty. RESULTS Medical history of 37 patients (16.3 %) included infection of or a risk-associated procedure on the urogenital system (endoscopic or open surgery, prostate gland biopsy, extracorporeal lithotripsy). Six patients (2.6 %) underwent surgery with possible bacteremia (intestine resection for tumor, 2x; surgery for paronychium, 2x; cholecystectomy, 1x; and appendectomy, 1x). Dental surgery or mouth disease was recorded in 11 patients (4.8 %). DISCUSSION The authors suggest that the orthopedic surgeons performing joint replacement should assume their deal of responsibility and should provide relevant, comprehensive information to both the patient and the attending physician. These surgeons should be ready to remain involved in their patients' further therapies and, after assessing all risks, should be able to recommend an optimal prophylactic treatment. The introduction of a new preventive approach requires a simple and uncomplicated scheme. Any complicated and expensive system of preventive antibiotic administration will only meet with lack of understanding and with trivialization. The requirement that antibiotic treatment should be selected according to the site and type of risk-associated disease is logical, but, in our opinion, rather formal and unrealistic. The authors prefer a simple system permitting a rapid and overall introduction of preventive measures. CONCLUSIONS The groups of patients indicated for prevention of late hematogenous infection of prosthetic joints are clearly defined and, by no means, do they involve all patients with total joint replacement.

Článek

Cefalosporiny 1. a 2. generace

Cermanová, Jolana, 1965-
Autor Autorita ORCID Ústav farmakologie, Lékařská fakulta UK, Hradec Králové

Causa subita. 2004 ; 7 (9) : 356-358.

Causa subita (Praha)
ISSN 1212-0197
Medvik
Zdroj

Článek

Cefalosporinová antibiotika v rukou praktického lékaře

Dlouhý, Pavel, 1961-
Autor Autorita

Causa subita. 2003 ; Roč. 6 (č. 1) : s. 20-23.

ISSN 1212-0197
Medvik
Zdroj

Přehledný článek shrnuje společné znaky cefalosporinových antibiotik, jejich rozdělení, farmakokinetické vlastnosti, nežádoucí účinky. Podrobně uvádí charakteristiky perorálních cefalosporinů I., II. a III. generace, jejich indikace a dávkování.